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ABSTRACT
Drug-induced liver injury (DILI) is an important cause of drug
toxicity. Inhibition of multidrug resistance protein 4 (MRP4), in
addition to bile salt export pump (BSEP), might be a risk factor for
the development of cholestatic DILI. Recently, we demonstrated
that inhibition of MRP4, in addition to BSEP, may be a risk factor for
the development of cholestatic DILI. Here, we aimed to develop
computational models to delineate molecular features underlying
MRP4 and BSEP inhibition. Models were developed using 257 BSEP
and 86 MRP4 inhibitors and noninhibitors in the training set. Models
were externally validated and used to predict the affinity of
compounds toward BSEP and MRP4 in the DrugBank database.
Compounds with a score above the median fingerprint threshold
were considered to have significant inhibitory effects on MRP4 and
BSEP. Common feature pharmacophore models were developed
for MRP4 and BSEP with LigandScout software using a training set
of nine well characterized MRP4 inhibitors and nine potent BSEP
inhibitors. Bayesian models for BSEP and MRP4 inhibition/
noninhibition were developed with cross-validated receiver oper-
ator curve values greater than 0.8 for the test sets, indicating
robust models with acceptable false positive and false negative
prediction rates. Both MRP4 and BSEP inhibitor pharmacophore
models were characterized by hydrophobic and hydrogen-bond
acceptor features, albeit in distinct spatial arrangements. Similar
molecular features between MRP4 and BSEP inhibitors may
partially explain why various drugs have affinity for both trans-
porters. The Bayesian (BSEP, MRP4) and pharmacophore (MRP4,
BSEP) models demonstrated significant classification accuracy
and predictability.
Introduction
Drug-induced liver injury (DILI) is an important cause of drug toxicity
and a major reason for withdrawal of drugs from the market (Abboud
and Kaplowitz, 2007) or attrition of drug candidates in late development
stages, which can be extremely costly. Unfortunately, current in vitro
screens or in vivo preclinical studies cannot accurately predict the
potential of compounds to cause hepatotoxicity. DILI remains a major
concern in drug discovery and clinical development. This obstacle has
necessitated a search for alternative technologies, such as computational
approaches, to decrease the risk of DILI-associated late-stage failures.
Despite extensive research, the underlying mechanisms of DILI
are not well understood. However, it is clear that compound-related
properties as well as individual patient characteristics affect the
occurrence of DILI. Formation of reactive metabolites, mitochondrial
impairment, and inhibition of canalicular bile acid transport mediated by
the bile salt export pump (BSEP) (e.g., troglitazone, bosentan, and
erythromycin) (Stieger et al., 2000; Fattinger et al., 2001; Kostrubsky
et al., 2003) are known risk factors for the development of DILI in
humans. This has been substantiated by large-scale in vitro screening
studies revealing that drugs that cause cholestatic DILI have higher
potencies as well as frequencies of BSEP inhibition compared with
drugs that are not liver toxic or that cause hepatocellular DILI (Morgan
et al., 2010; Dawson et al., 2012). BSEP is located at the canalicular
membrane of the hepatocyte, where it is involved in the excretion of bile
acids into bile under physiologic conditions (Noe et al., 2002). The
importance of this protein in bile acid homeostasis is emphasized by the
observation that mutations in the BSEP gene ABCB11 have been
associated with progressive familial intrahepatic cholestasis type 2.
Although BSEP inhibition may explain bile acid–mediated DILI liability
for a large proportion of compounds, a subset of hepatotoxic drugs
remains that cannot be explained by BSEP inhibition alone.
In addition to canalicular BSEP, multidrug resistance protein 4
(MRP4) is a bile acid efflux protein localized at the basolateral
membrane of hepatocytes. While hepatic expression is low under
normal physiologic conditions, MRP4 up-regulation has been
demonstrated under cholestatic conditions. MRP4 is hypothesized to
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serve as a back-up system for bile acid efflux from hepatocytes into
sinusoidal blood when the normal vectorial transport of bile acids from
hepatocytes into bile is compromised (Scheffer et al., 2002; Teng and
Piquette-Miller, 2007; Gradhand et al., 2008; Chai et al., 2012).
Recently, we screened 88 drugs (BSEP inhibitors and noninhibitors) for
inhibition of MRP4-mediated transport of the prototypical substrate
[3H]-dehydroepiandrosterone sulfate (DHEAS) and discovered potent
MRP4 inhibition among cholestatic BSEP noninhibitors. A statistically
significant relationship was observed between the potency of MRP4
inhibition and the probability of cholestatic classification. For each 1%
increase in MRP4 inhibition, the probability that a drug was cholestatic
increased by 3.1%. Interestingly, many BSEP inhibitors were also
MRP4 inhibitors. These data suggested that MRP4 inhibition may serve
as a confounding factor in BSEP-mediated DILI or, in some cases, lead
to DILI in the absence of BSEP inhibition. Thus, MRP4 inhibition may
be an additional risk factor for the development of cholestatic DILI.
The role of hepatic bile acid transport inhibition in the etiology of
DILI emphasizes the urgent need to develop screening tools to
accurately predict drug–bile acid transporter interactions. While in vitro
membrane vesicle assays have been developed for BSEP and MRP4
screening, use of these assays early in drug development is time
consuming, labor and resource intensive, and requires the physical
availability of compounds (including metabolites) for testing. An
alternative approach to in vitro testing is the use of computational
models to predict drug–bile acid transporter interactions and aid in
identifying transporter-associated DILI early in the drug discovery
process. For example, pharmacophore models have been used in ligand-
based drug design to define the key structural characteristics that
a molecule must possess to bind to the biologic target (Ekins et al.,
2012). Since models for BSEP have been reported recently (Pedersen
et al., 2013; Ritschel et al., 2014), the aim of the current study was to
develop a comprehensive model for MRP4 inhibition and evaluate
its predictive ability. In addition, we developed Bayesian models to
delineate molecular features underlying both MRP4 and BSEP
inhibition. These in silico models were used to identify potential novel
MRP4 inhibitors by virtual screening of an existing database and
classify drugs as BSEP and MRP4 inhibitors in an effort to correlate
these features with DILI incidence.
Materials and Methods
Dataset Composition. A dataset of 86 compounds derived from Köck et al.
(2014) was used for MRP4 inhibition modeling, and a dataset of 257 compounds
derived from Dawson et al. (2012) and Morgan et al. (2013) was used to develop
BSEP inhibition models. The compounds in these datasets were structurally
diverse and from various therapeutic classes. They were classified as cholestatic
or noncholestatic, according to the DILI type reported in the literature. The
compounds were further classified as active for the specified transporter if they
had an IC50 # 135 mM for BSEP or a percent inhibition $ 21% compared with
control at 100 mM for MRP4; otherwise, they were classified as inactive against
that transporter. The MRP4 classifications are based on findings by the Köck
et al. that compounds that inhibit by at least 21% have a 50% chance of being
cholestatic and the rationale for the BSEP classifications is to identify inhibitor
compounds with both potent and moderate cholestatic risk, similar to Morgan
et al. These classifications enable the identification of compounds that should be
investigated further for their potential to cause cholestasis.
In addition to MRP4 and BSEP datasets, a database of 1510 U.S. Food and
Drug Administration–approved drugs was retrieved from DrugBank (http://
www.drugbank.ca) (Law et al., 2014). The database was modified by removing
ionic salts and large polymeric drugs and proteins, resulting in a catalog of
1488 drugs.
Training and Test Set Generation. The MRP4 and BSEP databases were
separated into training and test sets by randomly dividing two-thirds of the
compounds into the training set and the other one-third into the test set
(Supplemental Table 1). Table 1 enumerates the number of compounds in each
set based on the respective transporter as well as the number of compounds that
were classified as inhibitors and noninhibitors.
The Bayesian modeling of MRP4 and BSEP used all the compounds in their
respective training sets. In contrast, the pharmacophore models were developed
using a subset of compounds from the training set. The MRP4 pharmacophore
subset was based on clustering of the training set, which produced a subset of
nine compounds. Analogously, the BSEP pharmacophore subset contained the
strongest inhibitors, also producing a subset of nine compounds. Details of
subset generation and composition are explained further within the pharma-
cophore creation methods section.
The conformational models for pharmacophore creation were produced in
LigandScout using the OMEGA conformer generator with the default best quality
settings, which produced a maximum of 500 conformations per molecule with
an energy window of 10 kcal/mol and root-mean-square threshold difference of
0.4 to identify unique conformers. The common feature pharmacophore was
generated using the default settings in LigandScout for ligand-based shared-
feature pharmacophore creation with a feature tolerance scale of 1.0.
Principal Component Analysis of Training, Test Set, and DrugBank
Molecules. The three-dimensional molecular structures of 86 MRP4 inhibitors
and noninhibitors and the 257 BSEP inhibitors were obtained from PubChem
(http://www.ncbi.nlm.nih.gov/pccompound). Principal component analysis
(PCA) plots of each transporter’s training and test sets were produced to ensure
that the two sets were representative of each other in terms of molecular
descriptors. In addition, the training sets were compared with the modified
DrugBank database (see above) to ensure that the training set was representative
of currently approved drugs and had predictive power in that chemical space. The
PCA plots were generated based on eight molecular descriptors for each drug:
ALogP, molecular weight, number of hydrogen bond donors, number of
hydrogen bond acceptors, number of rotatable bonds, number of rings, number of
aromatic rings, and molecular fractional polar surface area. The molecular
descriptors and PCA plots were generated within Discovery Studio 4.0 (DS 4.0)
(Accelrys, Inc., San Diego, CA). The two-dimensional plots (Fig. 2) represent
only the first two principal components of each comparison for visual clarity.
Common Feature Pharmacophore Generation and Validation. Ligand-
based pharmacophores and conformational models were generated using
LigandScout (version 3.12, build 20130912; Inte:Ligand, Vienna, Austria) [1,2]
with default settings. The pharmacophore models for MRP4 inhibition were
generated from a subset of drugs produced by clustering the training sets based on
similarity of the pharmacophore radial distribution function. Drugs with similar
pharmacophore features were clustered together, and the most potent inhibitors of
each cluster were included in the subset to train the pharmacophore model. The
rationale of clustering is to generate a pharmacophore from a smaller training set
while still maintaining the structural diversity of the original training set. If the
common pharmacophore creation failed or produced a pharmacophore with less
than three features, the drug that failed to align was removed from the training set.
Of the 10 pharmacophores generated per training set, the pharmacophore that
aligned with the most compounds in the training and test set and had the highest
score was selected for further testing.
The MRP4 common feature pharmacophore was validated within LigandScout
through virtually screening the test set for its ability to distinguish actives
(i.e., drugs with$ 21% MRP4 inhibitory activity) from inactives (i.e., drugs with
, 21%MRP4 inhibitory activity). The conformational models of the test set were
generated in an identical manner as the training set. Drugs that aligned with all
three pharmacophore features were predicted to be active MRP4 inhibitors.
TABLE 1
Composition of training and test set
Transport Model MRP4 BSEP
Training set total (inhibitors/noninhibitors) 57 (34/23) 171 (43/128)
Test set total (inhibitors/noninhibitors) 29 (17/12) 86 (22/64)
Pharmacophore training subseta 9 9
Pharmacophore test setb 77 247
aSubset of drugs from the training set used to develop the pharmacophore.
bDrugs not included in the pharmacophore training set were moved to the test set.
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The pharmacophore models for BSEP inhibition were generated from
a subset of drugs from the BSEP training set that were the strongest inhibitors
(, 25 uM IC50s) among the Morgan dataset (Morgan et al., 2013). This dataset
was chosen because it contained the largest number of BSEP inhibitors. The
clustering method used for the MRP4 inhibition pharmacophore was used
initially; however, this resulted in a pharmacophore with poor predictive ability,
which is why the strongest inhibitors were used instead. The BSEP common
feature pharmacophore was validated using the same methods as the MRP4
pharmacophore, except that actives were drugs with an IC50 # 135 mM.
Building and Validation of Bayesian Models. Bayesian categorization
involves simple and straightforward probabilistic classification by evaluating
the frequency of structural features associated with a hypothesis of interest (Xia
et al., 2004). The protocol “Create Bayesian Model” in DS 4.0 was applied for
model generation, with the number of bins set to 10. In addition to seven
molecular descriptors, extended-connectivity fingerprints maximum diameter 6
(ECFP_6) and functional-class fingerprints maximum diameter 6 (FCFP_6)
(Rogers et al., 2005) were calculated for all compounds. ECFP and FCFP differ
such that, for example, a chlorine atom and a bromine atom, which are
substituents in the same position on an aromatic ring, would be differentiated as
different fingerprints with ECFP but not with FCFP. The models were built by
using combinations of iterative sets of varying descriptors and cutoff values.
Bayesian models were validated with a 10-fold cross-validation–based receiver
operator curve (ROC) area under the curve (AUC) (XV ROC AUC) (Zweig and
Campbell, 1993) associated with training set compounds. The predictive
capacity of Bayesian models was validated with the same test set described for
the pharmacophore generation above. The activities of the test set compounds
were predicted by the “Calculate Molecular Properties” protocol in DS 4.0.
Evaluation of Model Performance. The Matthews correlation coefficient
(MCC) was used to determine the relative predictive ability of the pharmacophore
and Bayesian models. MCC ranges from –1 (no correlation) to +1 (full
correlation) and is calculated as follows:
MCC ¼ TP TN2 FP FNffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiðTPþ FPÞðTPþ FNÞðTNþ FPÞðTNþ FNÞp ð1Þ
where TP = number of true positives; FP = number of false positives; TN =
number of true negatives; and FN = number of false negatives. Positive
predictive value = TP/(TP+FP); sensitivity = TP/(TP+FN); and specificity =
TN/(TN+FP).
The ROC curve is another method for evaluating models. It is a two-
dimensional plot that graphs the sensitivity of a model, its true positive rate,
versus the reverse percentage of the specificity of the model, its false positive
rate, by the ranked order of the pharmacophore-fit scores. One of the abilities of
the ROC curve is the use of the AUC when comparing the ability of different
models to correctly classify true positives above false positives. Starting from
the bottom left corner, the graph plots the percentage of the actives in the test
set properly classified as active, which is defined as the sensitivity or true
positive rate, versus the percentage of the inactives improperly classified as
active, which is defined as the reverse specificity or false positive rate. In
addition to the AUC, the ROC can be used to set a score cutoff that optimizes
the tradeoff between sensitivity and specificity.
Results
Characteristics of the Dataset. The MRP4 inhibitor data were
obtained from data previously generated in our laboratories (Köck
et al., 2014), and the BSEP inhibitor data were compiled from two
high-throughput screening studies (Dawson et al., 2012; Morgan et al.,
2013). The BSEP studies were selected due to the large number of
screened compounds from various therapeutic areas (Supplemental
Table 1). Venn diagrams reveal the composition of the MRP4 inhibitor
dataset contrasted with the BSEP data from Morgan et al. to illustrate
compounds in the dataset that uniquely inhibit MRP4 or BSEP as well
as compounds that inhibit both transporters simultaneously (Fig. 1).
These diagrams demonstrate that most of the previously identified
BSEP inhibitors tested by our laboratories were also MRP4 inhibitors
(Fig. 1A). Among cholestatic compounds, most were dual BSEP and
MRP4 inhibitors or MRP4-only inhibitors. Only one BSEP-only
inhibitor had been identified as cholestatic (Fig. 1B).
Structure Generation and Validation. The PCA plot is a useful
tool to predict potential outliers by assessing similarity among training
and test set compounds (Khandelwal et al., 2007). For the MRP4 dataset,
the PCA of 86 training and test set drugs with at least three principal
components was performed based on eight descriptors. There were 57
compounds from the training set and 29 from the test set. The first and
second components accounted for 36.6% and 27.2% of the total
variance. For the BSEP dataset, the PCA of 257 compounds compared
171 and 86 compounds in the training and test sets, respectively. The
first and second components accounted for 39.1% and 34.4% of the total
variance, indicating that these components represented the majority of
the overall descriptor space occupied by the molecules. Figure 2, A and
B demonstrate that the test set drugs accommodate a similar space
compared with the training set compounds for their respective
transporter. PCA plots of the compounds in the training sets are overlaid
on a PCA plot of DrugBank drugs in Fig. 2, C and D, illustrating that
training set compounds cover most of the descriptor space occupied by
the compounds featured in the DrugBank database.
Building and Validation of Bayesian Models. Bayesian models for
MRP4 inhibition were developed with a training set of 57 MRP4
inhibitors and noninhibitors, and the Bayesian models for BSEP
inhibition were developed with a training set of 171 inhibitors and
noninhibitors. Eight structural descriptors as well as structural extended-
connectivity or functional-class fingerprints (ECFP_6 or FCFP_6; see
Materials and Methods) were incorporated for model development.
Four Bayesian models were generated for MRP4 and BSEP inhibitors
and noninhibitors based on specified atom type (ECFP) and functional
class (FCFP) two-dimensional substructure fingerprints.
The predictive performance of Bayesian models was evaluated
by XV ROC AUC based on 10-fold cross-validation of the training
set compounds. XV ROC AUC reflects the relationship between
sensitivity and specificity, ranging from 0 to 1, with a higher number
indicating a better model (Zweig and Campbell, 1993; Obuchowski
and Lieber, 1998). The Bayesian models were also validated with their
respective test set, consisting of 29 drugs for the MRP4 model and
86 drugs for the BSEP model. Their predicted performance was
established by sensitivity, specificity, overall prediction accuracy,
and MCC values (a measure of the quality of binary classifications)
calculated from the empirical true positive, true negative, false
positive, and false negative values (Ung et al., 2007; Khandelwal
et al., 2008) (Table 2).
Table 2 shows the AUCs of Bayesian models based on the 10-fold
cross-validation with training set compounds. AUC values range be-
tween 0 and 1, with 0.5 indicating 50% correct prediction and 1 in-
dicating a perfect match between observed and predicted data (Fawcett,
Fig. 1. (A) Classification of the inhibitors used in development of the MRP4
models. Forty-five drugs were MRP4 inhibitors only and 31 drugs were BSEP
inhibitors only, whereas 26 molecules inhibited both MRP4 and BSEP. (B) Of the
compounds in (A), 14 MRP4 inhibitors were cholestatic, whereas only one BSEP
inhibitor was identified as a cholestatic drug. Of the 26 compounds classified as both
MRP4 and BSEP inhibitors, 15 (58%) were clinically identified as cholestatic.
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Fig. 2. (A) MRP4: PCA of the training and test set compounds (257 in total) were selected such that they occupy similar areas of the PCA plot. The PCA among the training
and test set compounds was generated with the following properties: ALogP, molecular weight, molecular fractional polar surface area, number of rings, aromatic rings,
rotatable bonds, hydrogen bond acceptors, and hydrogen bond donors. The first principal component explains 0.366 of total variance, and the second principal component
explains 0.272 of total variance. When combined, these explain 0.638 of total variance. The principal components are linear combinations of original descriptors. The
dominate descriptors in the principal components are determined by the product of the descriptor coefficient while accounting for the magnitude of the descriptor. The first
principal component is dominated by molecular weight, number of hydrogen bond acceptors, and number of rotatable bonds. The second principal component is dominated
by the molecular fractional polar surface area. Component 1 = 23.8514 + 0.17609 * [ALogP] + 0.0029942 * [Molecular_Weight] + 0.19241 * [Num_H_Donors] + 0.12966 *
[Num_H_Acceptors] + 0.11058 * [Num_RotatableBonds] + 0.21601 * [Num_Rings] + 0.26649 * [Num_AromaticRings] 2 0.91018 * [Molecular_FractionalPolarSurfa-
ceArea]. Component 2 = 20.91763 2 0.22028 * [ALogP] + 0.00060715 * [Molecular_Weight] + 0.30038 * [Num_H_Donors] + 0.1113 * [Num_H_Acceptors] +
0.0097512 * [Num_RotatableBonds] 2 0.15452 * [Num_Rings] 2 0.34347 * [Num_AromaticRings] + 4.3042 * [Molecular_FractionalPolarSurfaceArea]. (B) BSEP: PCA
analysis of the training and test sets. The first and second principal components accounted for 0.391 and 0.344 of total variance, respectively. Together, they explain 0.735 of
total variance. The first principal component (x-axis) is governed by the number of hydrogen bond donors/acceptors and number of rings, whereas the second principal
component (y-axis) is governed by lipophilicity and the number of aromatic rings. Both principal components are strongly influenced by the fractional polar surface area.
Component 1 = 24.0005 + 0.035399 * [ALogP] + 0.0031256 * [Molecular_Weight] + 0.16608 * [Num_H_Donors] + 0.14138 * [Num_H_Acceptors] + 0.11881 *
[Num_RotatableBonds] + 0.23456 * [Num_Rings] + 0.23836 * [Num_AromaticRings] + 0.48987 * [Molecular_FractionalPolarSurfaceArea]. Component 2 = 20.12988 +
0.2367 * [ALogP] + 0.00047919 * [Molecular_Weight] 2 0.20734 * [Num_H_Donors] 2 7.2971e-002 * [Num_H_Acceptors] + 0.019248 * [Num_RotatableBonds] +
0.16242 * [Num_Rings] + 0.31811 * [Num_AromaticRings] 2 3.6221 * [Molecular_FractionalPolarSurfaceArea]. PCA analysis comparing the training set of MRP4 (C)
and BSEP (D) to the DrugBank database of U.S. Food and Drug Administration–approved drugs.
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2006). The AUC values associated with the four individual models
indicated good internal consistency and prediction accuracy. While both
the MRP4 inhibitor and the BSEP inhibitor Bayesian classification had
similar ROC AUC scores for both the internal leave-one-out cross-
validation and the external test set validation, the sensitivity and
specificity varied more between the models. The MRP4 inhibitor
models had a significantly lower sensitivity, especially the MRP4 ECFP
model, compared with the BSEP inhibitor models, but the trade-off was
a higher specificity, minimizing false positives. Bayesian classification
modeling of BSEP inhibitors resulted in more predictive models, as
demonstrated by their relatively higher Matthews correlation coefficient
compared with MRP4 inhibitor models, which could be due to the
larger size of the training set (171 BSEP compounds versus 59 MRP4
compounds). In addition to the external validation performed here, the
BSEP Bayesian FCFP model was used to predict the classification of
five strong inhibitors and five noninhibitors from a previous screen for
BSEP inhibitors (Pedersen et al., 2013). The model was able to correctly
classify 9 of the 10 compounds, only incorrectly classifying MK571 as
a noninhibitor.
Fingerprints can be defined as molecular fragments that characterize
the structural features of drug molecules. Figures 3 and 4 display
the five most predictive structural fragments for both favorable and
TABLE 2
Characteristics of Bayesian Models for MRP4 and BSEP Inhibition
Bayesian models MRP4inhib-ECFP_6 MRP4inhib-FCFP_6 BSEPinhib-ECFP_6 BSEPinhib-FCFP_6
Two-dimensional fingerprints ECFP_6 FCFP_6 ECFP_6 FCFP_6
10-fold XV ROC AUCa 0.816 0.793 0.750 0.759
TP/FN/FP/TNa 33/1/1/22 33/1/1/22 43/0/3/125 43/0/5/123
External validationb 0.819 0.838 0.845 0.871
TP/FN/FP/TNb 8/9/1/11 10/7/2/10 18/4/15/49 17/5/10/54
SE (%)b 47.1 58.8 81.8 77.3
SP (%)b 91.7 83.3 76.7 84.4
Q (%)b 65.5 69.0 77.9 82.6
MCCb 0.4123 0.4216 0.5238 0.5796
FN, false negative; FP, false positive; Q, overall prediction accuracy; SE, sensitivity; SP, specificity; TN; true negative; TP, true positive.
aXV ROC AUC based on training set compounds (green shaded region).
bPredictive performance validation by test set compounds (blue shaded region) (Ung et al., 2007; Khandelwal et al., 2008). SE = TP/(TP
+ FN); SP = TN/(TN + FP); Q = (TP + TN)/(TP + TN + FP + FN); MCC = [(TP * TN) – (FN * FP)]/[(TP + FP)(TP + FN)(TN +FN)(TN
+FP)]1/2.
Fig. 3. Favorable and unfavorable molecular features for interactions with MRP4. Each feature is a fragment-like fingerprint, up to six bond lengths in diameter, which
occurs within the larger parent molecule. The squiggle and asterisks indicate that the bond extends further but does not specify the atom type. The favorable features or good
features are labeled G1–G5, and the unfavorable features or bad features are labeled B1–B5. A feature is considered good if it frequently occurs within compounds that were
classified as inhibitors and bad if it frequently occurs in compounds that are noninhibitors. The large integer after the colon is the unique hash identifier for the shown
fingerprint. The Bayesian score is the normalized probability assigned to that feature.
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unfavorable inhibitory activity against MRP4 and BSEP using
FCFP_6 fingerprints. Supplemental Figure 2 contains an expanded
figure of structural fragments favorable and unfavorable for inhibition
of MRP4 and BSEP using both FCFP_6 and ECFP_6 fingerprints.
Structural elements depicted in Figs. 3 and 4 were identified in inhibitors
and noninhibitors among the training set compounds, respectively.
Oxygen atoms tended to be predictive of favorable inhibitory activity for
both MRP4 and BSEP; however, negatively ionized oxygen atoms
frequently occurred in the MRP4 model but not in the BSEP model even
though both are considered anion transporters. This is in agreement with
the study by Pedersen et al. (2013) who reported that BSEP substrates
tend to be anionic but inhibitors were more likely to be neutral at
a physiologic pH. Accordingly, positively charged secondary and
tertiary amines frequently occur among the MRP4 fingerprints
associated with noninhibition. Thus, the identified fingerprints could
be helpful in distinguishing inhibitors and noninhibitors of MRP4
among novel compounds.
MRP4 Pharmacophore Development. The MRP4 training set of
57 drugs was imported into LigandScout 3.12 and clustered according
to pharmacophore radial distribution function-code similarity, with the
maximum conformations set to three and the cluster distance set to
0.5. This algorithm clusters compounds that have similar individual
three-dimensional pharmacophore characteristics.
The following nine drugs that represent the strongest inhibitors in their
respective cluster were used to generate MRP4 inhibition pharmaco-
phores: nitrenedipine, sulindac, sorafenib, clobetasol propionate, benz-
bromarone, glafenine, furosemide, finasteride, and simvastatin. The
remaining 77 compounds not selected for the training set were moved to
the test set for pharmacophore validation. The ligand-based common
feature pharmacophore produced from the nine compounds had two
hydrophobic features and a hydrogen bond acceptor feature (Fig. 5A).
The two hydrophobic features were 5.01 Å apart, while the hydrogen
bond acceptor was 4.81 Å from the neighboring hydrophobic feature and
8.86 Å from the distal hydrophobic group. All nine drugs in the training
set aligned with all three pharmacophore features. Two representative
compounds were aligned to the pharmacophore to illustrate scale and
similarity in how the molecules align with the respective molecular
features comprising the pharmacophore (Fig. 5B). These compounds
were chosen because their steroid backbone renders them particularly
rigid, increasing the likelihood that the representative conformer is close
to its bioactive conformation. Additionally, they contain few atoms that
can engage in intermolecular interactions, which further confirms that
these are the requisite features for MRP4 recognition. Exclusion
volumes, i.e., spheres that cannot be occupied and represent steric
hindrance, were generated initially using the noninhibitors in the
57 compound training set; however, consideration of exclusion volumes
rendered the models more likely to incorrectly classify MRP4 inhibitors
as noninhibitors during external validation and were subsequently
omitted during database screening.
Quantitative Validation of the MRP4 Pharmacophore Model.
The MRP4 pharmacophore model was able to correctly classify 30 of
the 42 actives in the test set and 22 of the 35 inactives, featuring a model
sensitivity of 71.4% and specificity of 62.8%. The area under the
receiver operating characteristic curve was 0.70, which is considered
a fair quality model (Fig. 6).
Based on the virtual screening results from the external test set
validation, the model has its highest positive predictive value, the
number of true positives over the sum of true and false positives, at
a pharmacophore-fit score cutoff of 37.75. The positive predictive
value of the model at this cutoff is 0.826, selecting 19 true positives,
45.2% of total actives in the set, but only four false positives, 11.4% of
total inactives in the set. The pharmacophore-fit score cutoffs allow for
Fig. 4. Favorable and unfavorable molecular features for interactions with BSEP.
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selecting drugs with a higher likelihood of being classified correctly
beyond those that align to the pharmacophore within the tolerance of
the features.
The inactives that were incorrectly classified included dexamethasone,
naloxone, clopamide, vinblastine, tolbutamide, probenecid, indinavir,
flupirtine, chorpropamide, alprenolol, chlorpheniramine, fluorescein, and
timolol. Interestingly, the false positive with the highest pharmacophore-
fit score was dexamethasone, a glucocorticoid that had no significant
inhibitory activity (5 6 34%). This compound was aligned with
clobetasol propionate, another glucocorticoid included in the nine
training set compounds, which was a strong inhibitor (101 6 23%)
(Fig. 7).
As can be seen in Fig. 7, clobetasol propionate (orange) and
dexamethasone (gray) have a high degree of structural similarity. From
this observation, molecular properties that could be mediating the
significant difference in inhibitory activity were investigated. The
molecular property that exhibited the most significant difference was
calculated log P, which is 4.18 for clobetasol propionate and 1.68 for
dexamethasone, rendering clobetasol propionate a more hydrophobic
compound. The difference in calculated log P values was evaluated for
all 87 compounds tested by Köck et al. Actives trended toward higher
log P values than inactives. A Pearson correlation coefficient for the
calculated log P and a compound considered active ($ 21% MRP4
inhibition) was 0.634, and the correlation coefficient for the percent
MRP4 inhibition and calculated log P was 0.508. Fig. 8 represents a box
plot of the calculated log P values for the compounds classified as
inactives and actives. The mean and median of the inactives’ calculated
log P values were 0.38 and 0.69, respectively, and the actives’ calculated
log P values were 3.64 and 3.84, respectively. It is interesting to note
that numerous sulfonamides or sulfamides, such as clopamide,
tolbutamide, probenecid, and chlorpropamide, were classified as false
positives. These molecules may either be a poor match to the models
or their features are incorrectly parameterized within the Bayesian and
pharmacophore modeling algorithms.
The actives that were not properly classified as active by the model
included 19-norethindrone, clozapine, desipramine, diphenhydramine,
etoposide, maprotiline, nitrofurantoin, nortriptyline, oxybutynin,
praziquantel, promethazine, and ticlodipine. Eight of these 12 drugs
have similar structures containing an amine group, which is predicted
to be positively ionized at a physiologic pH. In addition, six of these
drugs contain two aromatic rings whose distance is comparable to the
distance observed between the two hydrophobic features in the
MRP4 model. Compounds that fall into this category are clozapine,
desipramine, diphenhydramine, maprotiline, nortriptyline, and prom-
ethazine. Oxybutynin and ticlodipine contain an amine predicted to be
positively charged, but they have only one aromatic group. Nitro-
furantoin is a compound that continually failed to match any structural
similarity search to other known inhibitors; therefore, we speculate
that it is binding in a different manner than any of the other inhibitors,
perhaps at an allosteric site of the transporter.
Qualitative Validation of the MRP4 Inhibitor Model. In addition
to the quantitative validation from virtually screening the test set, two
compounds that qualitatively strengthen confidence in the model are
DHEAS, the substrate used to generate the data, and felbinac, a potent
MRP4 inhibitor from a separate screening of MRP4 inhibitors
(Morgan et al., 2013). DHEAS was not included in either the training
set or the test set, but the MRP4 pharmacophore model would be
expected to align to the substrate that was used experimentally to
generate the inhibition data. Figure 9A depicts how the two methyl
groups on DHEAS align to the hydrophobic features in the
pharmacophore, and one of the oxygen atoms from the sulfate group
aligns with the hydrogen bond acceptor feature. The alignment of the
pharmacophore model to DHEAS is of particular interest because of
its structural rigidity due to the steroid backbone structure. The only
significant intramolecular motion that DHEAS can undergo is the
rotation of the sulfate group. In addition to its rigidity, DHEAS
contains few atoms that can participate in intermolecular interactions.
Fig. 5. Pharmacophore model of inhibitors of MRP4-mediated transport of DHEAS.
(A) The pharmacophore model with the measured distances between the three features.
(B) The pharmacophore model aligned with chemical groups of two drugs from the
training set: clobetasol propionate (orange) and finasteride (lavender). Yellow spheres
represent hydrophobic features, and the red sphere represents a hydrogen bond
acceptor. On the stick model, red represents oxygen atoms, blue represents nitrogen
atoms, green represents halogen atoms, and the rest are carbons. Both hydrophobic
features align with methyl groups, and the hydrogen bond acceptor aligns with
a ketone group. Hydrogen atoms are not displayed for clarity.
Fig. 6. ROC curve of pharmacophore model of MRP4 inhibitors from virtually
screening the test set (N = 77 compounds).
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From the DHEAS pharmacophore (Fig. 9B), it appears that the two
methyl groups can participate in hydrophobic interactions, while the
ketone can be a hydrogen bond acceptor, and all the oxygen atoms in
the sulfate group, which is negatively ionized at physiologic pH, can
act as hydrogen bond acceptors.
Felbinac is of interest for the same reasons as DHEAS, namely, its
structural rigidity and minimal possible intermolecular interactions. In
addition, felbinac is a potent inhibitor of MRP4-mediated transport of
b-estradiol 17-(b-D-glucuronide), with an IC50 of 8.2 uM (Morgan et al.,
2013). Felbinac aligns well with the MRP4 pharmacophore model and,
as shown in Fig. 9D, engages in only a limited number of intermolecular
interactions. Both hydrophobic and aromatic interactions with the phenyl
groups in the biphenyl compound and the oxygen atoms of the negatively
ionized carboxylate group are able to act as hydrogen bond acceptors.
The two phenyl groups are locked rigidly on perpendicular planes and,
therefore, only the carboxylate group is able to rotate.
Log P Filtering Improves Model Specificity. The MRP4
pharmacophore model’s specificity can be significantly improved if the
test set was to be filtered after screening with a calculated log P cutoff of
2.92, which corresponds to the start of the lower quartile of the actives.
The sensitivity would decrease to 52.38% (22 true actives of 42 total
actives), but the specificity would increase to 91.43% (3 false actives of
35 total inactives). This marked improvement in specificity demon-
strates the significant influence log P plays in MRP4 inhibition.
BSEP Inhibitor Pharmacophore Development and Validation.
The BSEP inhibitor pharmacophore was produced with a subset of
drugs from the training set that represented the nine strongest BSEP
inhibitors, according to Morgan et al., which were also previously tested
for MRP4 inhibition by our group. This subset included nitrenedipine,
fenofibrate, ritonavir, pioglitazone, rosiglitazone, valinomycin, simva-
statin, benzbromarone, and lopinavir. The common feature pharmaco-
phore produced with this set of nine compounds had three features: two
hydrophobic features and one hydrogen bond acceptor (Supplemental
Fig. 1). This is similar to the MRP4 pharmacophore, which may explain
the high degree of inhibition overlap; however, the distances between
the features were different. The distance between the two hydrophobic
features was 6.29 Å, the distance between the hydrogen bond acceptor
and proximal hydrophobic feature was 4.67 Å, and the distance between
the hydrogen bond acceptor and distal hydrophobic feature was 6.69 Å.
All nine drugs that were used to train the pharmacophore hit all three
features.
The BSEP inhibitor pharmacophore was validated by virtual
screening of the test set, and the model correctly classified 46 of the 56
inhibitors and incorrectly classified 120 of the 191 noninhibitors. The
model selectivity was 82.7%, but the specificity was 37.2%. The poor
model specificity is partly due to the higher proportion of noninhibitors
to inhibitors in the test set (191 versus 56), but is also indicative of the
difficulty of modeling BSEP through a pharmacophore approach.
Discussion
A ligand-based pharmacophore and Bayesian modeling approach is
presented here, describing the molecular properties and chemical
features necessary for human MRP4 and BSEP interaction. Since these
transport proteins have been associated with DILI, these models may be
useful in predicting DILI liability of novel compounds. The models
were developed from our laboratories’ previous work and data from
other groups. An advantage of Bayesian classification modeling is the
ability to easily interpret how the model weighs the various molecular
properties, and which molecular properties are most predictive for
classification. The Bayesian classification model was developed by
creating up to 11 bins for each molecular property. For discrete
properties, such as the number of rings or the hydrogen-bond acceptor
atoms, all the compounds with the same value were put into the same
bin. For continuous properties, such as molecular weight or ALogP,
a bin was assigned a value range and all the compounds that fell within
that range were put into that bin. The ranges for binning continuous
values were created such that the number of compounds in each bin was
evenly distributed. A normalized probability was then calculated for
each bin according to the fraction of compounds in the bin that were
active, i.e., if all the compounds in a bin were active, that bin was
assigned a higher probability. The probability was normalized by
adjusting for bins with few compounds. A Bayesian score was then
calculated by summing the normalized probabilities of all the bins to
which a compound was assigned.
By inspecting the normalized probabilities of individual bins, the
molecular properties that contain bins with high probabilities indicate
molecular properties that are well correlated with either inhibition
or noninhibition. For example, with the MRP4 model, a trend was
observed with a higher ALogP correlating to MRP4 inhibition (14 of 15
Fig. 7. Structural alignment of glucocorticoids clobetasol propionate (orange) and
dexamethasone (gray). Clobetasol propionate, a potent MRP4 inhibitor, inhibits MRP4-
mediated transport of DHEAS by 101 6 23%. In contrast, dexamethasone exhibits no
significant inhibitory effect (5 6 34% inhibition). The orange circles indicate identical
chemical groups in proximity with each other. On the stick model, red represents
oxygen atoms, green represents halogen atoms, and the rest represents carbon atoms.
Fig. 8. MRP4: comparison of calculated Log P of compounds classified as inactive
(, 21% MRP4 inhibitory activity; n = 37) compared with those classified as active
($ 21% MRP4 inhibitory activity; n = 50). The mean and median log P values of the
inactives are 0.38 and 0.69, respectively, and 3.64 and 3.84, respectively, for the actives.
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drugs with an ALogP of 3.8 or higher were inhibitors, while only 2 of
12 drugs with a ALogP of 0.94 or lower were inhibitors). A trend was
also observed with large molecular weight drugs more likely to inhibit
MRP4 compared with smaller drugs (23 of 25 drugs with molecular
weight$ 356 Da). It should again be noted that the value range of a bin
for molecular properties that are continuous is a result of evenly
dividing the ordered drugs into 11 bins. In addition to those continuous
properties, 23 of 25 drugs with three or four rings were inhibitors
compared with 1 of 9 compounds with zero rings or one ring.
Compared with the MRP4 Bayesian model, the BSEP Bayesian
model was more predictive of negative properties, thus predicting
more noninhibitors than inhibitors. This is likely due to the fact that
the training set contained more noninhibitors relative to inhibitors
compared with the MRP4 training set. For the BSEP model, only 7 of
90 drugs with a molecular weight less than 337 Da were inhibitors.
Correspondingly, only 11 of 90 compounds with four or fewer
rotatable bonds were inhibitors and, similar to the MRP4 model, only
3 of 72 drugs with an ALogP of 2.03 or lower were inhibitors.
Potential biologic implications of the association between high
calculated log P values and MRP4 inhibition were considered. These
data lead to speculation that molecules must partition first into the bilayer
to be an inhibitor for MRP4 or that higher log P values correspond with
increased hydrophobic interactions within the protein environment, thus
rendering these molecules stronger competitive inhibitors.
It is worth mentioning that these computational models are based on
data collected from membrane vesicle assays, and this in vitro system
could have an influence on experimental transport inhibition results.
The methods generally involve short incubation periods with the test
compounds in which the degree of partitioning of the test compound
into the membrane of the vesicles could be in flux. If the test compound
exerts its inhibition while imbedded in the membrane, this could cause
a skew in the data, in which compounds with higher log P values have
a higher rate of partitioning into the membrane than those with lower log
P values (Nagar and Korzekwa, 2012).
Comparison with Previous Models. Previous studies identified
important molecular features for BSEP inhibition (Pedersen et al., 2013),
and pharmacophore models have been proposed for BSEP (Ritschel
et al., 2014) and MRP4 (Fukuda et al., 2013). While there was good
corroboration between the important molecular features, there were
several notable differences between the pharmacophores previously
reported and those developed here, which can be ascribed primarily to
differences in the training sets used to generate the pharmacophores.
Molecular properties that were reported previously to have
a statistically significant difference between strong BSEP inhibition
(. 50% inhibition) and noninhibitors were log D7.4, molecular weight,
saturated nonpolar surface area, log P, number of rotatable bonds,
unsaturated nonpolar surface area, number of hydrogen-bond accep-
tors, and net charge at pH 7.4. The molecular properties that remain
statistically significant for weak inhibitors (27–50% inhibition) and
noninhibitors were only molecular weight and saturated nonpolar
surface area. In comparison, our best Bayesian BSEP model (FCFP_6)
ranked the top four feature bins based on their normalized probability
in descending order: molecular weight, FCFP_6 fingerprint, number of
rotatable bonds, and ALogP. However, since a compound can have
only one value for a molecular property but multiple fingerprints, the
fingerprints tend to be the predominate factor influencing the final
Bayesian score for a compound. The pharmacophore model for BSEP
is also in agreement with these previously reported molecular
properties since they consisted of two hydrophobic features and
a hydrogen-bond accepting feature. The hydrophobic features were
associated with the nonpolar surface area and high log P, while the
hydrogen-bond accepting feature was associated with the number of
Fig. 9. DHEAS, an MRP4 substrate, and felbinac, an MRP4 inhibitor, aligned with
the MRP4 inhibitor pharmacophore. Both compounds are also depicted with their
individual pharmacophore, which shows all possible intermolecular interactions. (A)
DHEAS aligned to the MRP4 pharmacophore. (B) DHEAS pharmacophore showing
all possible intermolecular interactions. (C) Felbinac aligned to the MRP4
pharmacophore. (D) Felbinac pharmacophore showing all possible interactions.
Yellow spheres represent hydrophobic features, red spheres represent hydrogen
bond acceptor features, the red star represents a negatively ionizable feature, and the
purple torus represents an aromatic ring feature. On the stick models, red represents
oxygen atoms, yellow represents phosphorus atoms, and the rest represents carbon
atoms. Hydrogen atoms are not displayed for clarity.
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hydrogen bond acceptors correlated with inhibition. The presence of
only one hydrogen bond accepting features in the pharmacophore
model, however, suggests that a large number is not essential for
inhibition but could provide more opportunities for hydrogen bonding
in the correct spatial arrangement.
Two common feature MRP4 pharmacophores were reported pre-
viously in the same paper: one based on five protease inhibitors (PIs) and
the other based on a more diverse set of 10 drugs that were inhibitors
based on literature reports. The pharmacophore based on five PIs
resulted in a pharmacophore with four hydrogen bond acceptors
(HBAs), one hydrogen bond donor, and three hydrophobic features, and
the pharmacophore based on 10 drugs resulted in two HBAs and
a hydrophobic feature. The PI-based pharmacophore featured a large
number of features due to the small number of compounds in the training
set and their high degree of structural similarity, while the pharmaco-
phore based on 10 diverse compounds was based on the findings from
multiple laboratories. The MRP4 pharmacophore we developed is more
appropriate for predicting potential MRP4 inhibitors to identify the
cholestatic potential of compounds because it was based on data from
a single laboratory utilizing one assay, was developed based on a diverse
set of compounds, and contained a large number of inhibitors.
The other recently reported BSEP pharmacophore (Ritschel et al.,
2014) was trained using five compounds of limited structural diversity
and resulted in a pharmacophore that had eight features: four
hydrophobic features and two HBAs that had an associated vector
feature. The authors found the pharmacophore too stringent so they
modified it by making only four hydrophobic features in the core of
the pharmacophore essential. The advantage of the BSEP pharmaco-
phore presented in this paper is that it is derived from pharmaceuticals
instead of a chemical library and was developed with more diverse
compounds, which results in a pharmacophore with fewer features but
one more equipped to deal with a larger chemical space. The BSEP
pharmacophore reported in this paper, however, is able to align with
the hydrophobic and hydrogen bond accepting features of the
previously reported BSEP pharmacophore. This suggests that the
pharmacophore reported in this paper may be convergent with previ-
ously reported pharmacophore, although it is less stringent.
In conclusion, ongoing studies will use these models in an ensemble
fashion against drugs that are predicted to be MRP4 or BSEP inhibitors
to further validate the models. These models, when used in combination,
may aid in the a priori identification of potential cholestasis-inducing
compounds during the early stages of drug development.
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